Literature DB >> 21656235

Unmasking of neonatal renovascular hypertension by milrinone used for cardiac dysfunction.

Prema Ramaswamy1, Susan Schulman, Panayot Filipov, Juan C Kupferman.   

Abstract

A neonate initially presented with heart failure, with severe cardiac dysfunction confirmed by echocardiography, at 3 days of age. Blood pressure at presentation was in the high normal range. It was not until there was a rapid improvement of left-ventricular function on intravenous milrinone that the infant was noted to be hypertensive on day of life 7. It is noteworthy that milrinone, a drug with vasodilator and inotropic properties, paradoxically unmasked hypertension by rapidly improving left-ventricular function. Subsequent work-up showed the etiology of hypertension to be left renal artery stenosis. We present this case to alert clinicians to the rarer causes of left-ventricular dysfunction and to point out that its etiology, i.e., hypertension, may not be apparent until there is improvement in the systolic function of the left ventricle.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21656235     DOI: 10.1007/s00246-011-0027-4

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  12 in total

Review 1.  Neonatal hypertension: diagnosis and management.

Authors:  J T Flynn
Journal:  Pediatr Nephrol       Date:  2000-04       Impact factor: 3.714

Review 2.  The hypertensive neonate.

Authors:  R D Adelman
Journal:  Clin Perinatol       Date:  1988-09       Impact factor: 3.430

3.  Presentation and echocardiographic markers of neonatal hypertensive cardiomyopathy.

Authors:  Amy L Peterson; Peter C Frommelt; Kathy Mussatto
Journal:  Pediatrics       Date:  2006-07-31       Impact factor: 7.124

4.  Perinatal renal ischemia resulting in hypertensive cardiomyopathy.

Authors:  J M Saland; L Mahony; M Baum
Journal:  Pediatrics       Date:  2001-01       Impact factor: 7.124

5.  Evaluation and long-term outcome of pediatric renovascular hypertension.

Authors:  S J McTaggart; S Gulati; R G Walker; H R Powell; C L Jones; S Gelati
Journal:  Pediatr Nephrol       Date:  2000-09       Impact factor: 3.714

6.  Use of milrinone in the management of haemodynamic instability following duct ligation.

Authors:  Arvind Sehgal; Johny V Francis; Anthony I Lewis
Journal:  Eur J Pediatr       Date:  2010-09-17       Impact factor: 3.183

7.  Effect of milrinone on left ventricular relaxation and Ca(2+) uptake function of cardiac sarcoplasmic reticulum.

Authors:  M Yano; M Kohno; T Ohkusa; M Mochizuki; J Yamada; M Kohno; T Hisaoka; K Ono; T Tanigawa; S Kobayashi; M Matsuzaki
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-10       Impact factor: 4.733

8.  Report of the Second Task Force on Blood Pressure Control in Children--1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland.

Authors: 
Journal:  Pediatrics       Date:  1987-01       Impact factor: 7.124

9.  Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique.

Authors:  P L Ludmer; R F Wright; J M Arnold; P Ganz; E Braunwald; W S Colucci
Journal:  Circulation       Date:  1986-01       Impact factor: 29.690

10.  Neonatal hypertension and cardiac failure.

Authors:  K C Hawkins; A R Watson; N Rutter
Journal:  Eur J Pediatr       Date:  1995-02       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.